Kent H. Cheng is a Partner at VLP. He has been practicing intellectual property law since 1988, representing and advising clients who need to protect or license their inventions or need to know the risk of patent infringement in marketing their products. His experience includes patent litigation, patent portfolio strategy and management, technology licensing and patent and trademark procurement.

His practice includes obtaining patents worldwide in various technologies, including chemical, pharmaceutical, biotechnology, material science, electronics and optics. Clients that he has assisted in procuring and/or analyzing patents include Genzyme, U.S. Bioscience (now part of Medimmune), Hoffman-La Roche, Novartis, Sandoz, Hoechst (now part of Aventis), Boehringer Ingelheim, Galderma, ScinoPharm, Optimer Pharmaceuticals, Hon Hai Precision Industry, City University of New York and Academia Sinica. A patent covering a pharmaceutical product that was prosecuted to issuance by Kent was successfully asserted in litigation against an infringer in U.S. District Court for the District of Maryland.

Kent also regularly advises clients in analyzing and in preparing opinions on patent validity and infringement issues, and in due diligence matters relating to their patent portfolios for private placement and initial public offering. He has specific expertise in advising clients on patent issues arising from the filing for FDA approval of chemical and biologic drug products.

Education

  • J.D., Pace University, 1991
  • Ph.D., Brandeis University, 1979
  • B.A., Columbia University, 1974
  • “China’s Patent Application Boom” by Enshan Hong and Kent Cheng Daily Journal